• image01
  • image02
  • image03
  • image04
  • image05
  • image06
  • image07
  • image08
  • image09
  • image10
  • image11
1947 Apri Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen. 1947 画像
July Injection Product for Neutropenia, "PANILTIN", sales launched
1949 February Reishin Tanimura became the President.
September Company head office relocated to Higashi-ku, Osaka.
Manufacturing plant relocated to Ashiya-shi, Hyogo.
1951 June Agreement for the sole distribution of Senju Products through Takeda Pharmaceutical Company Limited.
1955 December Masao Yoshida became the President.
1958 December Ophthalmic Solution for Cataract, "KATALIN", sales launched. 　1958　画像
1962 December Itami Plant established for manufacturing of ingredients in Itami, Hyogo. 1962　画像
1965 April Artificial Tear Ophthalmic Solution, "MYTEAR", sales launched. 1965　画像
May Company head office relocated to Kita-ku, Osaka
1972 March Company head office and Osaka branch are relocated to Hiranomachi, Higashi-ku, Osaka 1972　画像
1974 June Fukusaki Plant for manufacturing established in Kanzaki-gun, Hyogo 1974　画像
June Shoji Yoshida became the President.
1978 November Company head office relocated in Hiranomachi, Higashi-ku, Osaka.
1980 February Ophthalmic Solution for exclusive use on contact lens, "MYTEAR CL", sales launched 1980　画像
1981 September Penicillin Antibiotic Ophthalmic Product, "SULPELIN", sales launched 1981　画像
1985 December Antifungal Ophthalmic Product, "PIMARICIN", sales launched
1987 January Intraocular Irrigating Solution, "OPEGUARD MA",sales launched.
1988 February Cephalosporin Antibiotic Ophthalmic Product, "BESTRON", sales launched 1988　February　画像
October NSAID Ophthalmic Solution, "NIFLAN", sales launched 1988　October　画像
1993 January Established a resident office in California, U.S.A.
February Established Kobe Creative Center 1993　画像
July Ophthalmic Viscoelastic Preparation, "OPELEAD", sales launched
1997 April Celebrated 50th anniversary of company foundation.
2000 July NSAID Ophthalmic Solution, "BRONUCK", sales launched
2001 April Established a laboratory in Oregon, U.S.A.
2004 May Established resident office in Amsterdam, Netherland 2004　画像
September Anti-infective Fluoroquinolone Ophthalmic Solution, "GATIFLO", sales launched
2006 April Established a liaison office SENJU USA, INC., in California, U.S.A.
Established a resident office in Beijing, China.
June Yukoh Yoshida became the President.
2008 May Established a liaison office Senju Medical Consulting (Shanghai) Co., Ltd., in Shanghai, China.
Ophthalmic Suspension for Spring Catarrh, "TALYMUS", sales launched 2008 May 画像
December Karatsu Plant for manufacturing established in karatsu-shi, Saga 2008 December 画像
2009 October "LUMIGAN" Ophthalmic Solution 0.03% for treatment of glaucoma and ocular hypertension, sales launched. 2009年　画像
2010 November Established a liaison office SENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) CO., LTD., in Beijing, China, followed by liquidation in July 2011 of Senju Medical Consulting (Shanghai) Co., Ltd.
2011 November Established a resident office in Hanoi, Vietnam.
2012 May "AIPHAGAN" Ophthalmic Solution 0.1% for treatment of glaucoma and ocular hypertension, sales launched. 2012年画像
December Established a resident office in Moscow, Russia.
2017 April Celebrated 70th anniversary of company foundation.
2018 February Completed construction of new corporate building. 2018年画像
June "IBULIEF" I.V. Injection 20 mg for treatment of patent ductus arteriosus in premature infants, sales launched.
August Established a liaison office Senju Poland Sp. z o.o., in Warsaw, Poland.
2019 April Established Kobe Innovative Center.
Jiangsu QianShou Pharmaceutical Co., Ltd. in Jiangsu Province, China, became a subsidiary company.		 2019年画像
June Shuhei Yoshida became President.
September Macrolide antibiotic "AZIMYCIN" Ophthalmic Solution 1% sales launched. 2019年画像
October Established a limited liability company and liaison office SENJU Pharmaceutical RUS, in Moscow, Russia.
December "AIBETA" Combination Ophthalmic Solution for treatment of glaucoma and ocular hypertension, sales launched. 2020年画像
2020 June "AILAMIDE" Combination Ophthalmic Suspension for treatment of glaucoma and ocular hypertension, sales launched. 2020年画像
2021 December “Ranibizumab BS Intravitreal Injection Kit 10 mg/mL ‘Senju’” for treatment of nAMD and mCNV, sales launched. 2021年画像
2022 April Launch of Distribution of Medical Devices
2023 February Launch of the supplement brand “onoono”